首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1407304

檢查點抑制劑難治性癌症市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按類型、按應用、地區、競爭細分

Checkpoint Inhibitor Refractory Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Application, By Region, By Competition

出版日期: 2023年11月07日 | 出版商:

TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2022 年，全球檢查點抑制劑難治性癌症市場價值為 324.9 億美元，預計在預測期內將強勁成長，到 2028 年CAGR為8.49%。檢查點抑制劑是一種免疫療法，透過阻斷癌細胞中的某些蛋白質來發揮作用，讓免疫系統更有效地辨識和攻擊癌症。癌症是全世界發病和死亡的主要原因。隨著全球人口老化，癌症發生率預計將增加，對癌症治療（包括檢查點抑制劑難治性癌症市場）的需求不斷成長。據世界衛生組織稱，癌症是全球主要死亡原因之一，2020 年將導致近 1,000 萬人死亡，近六分之一。例如，中國人民解放軍總醫院正在進行一項單獨使用GSL合成酶抑制劑或與免疫檢查點抑制劑合併使用GSL合成酶抑制劑治療晚期復發或難治性血液惡性腫瘤和先前治療過的實體腫瘤患者的I期試驗。

主要市場促進因素

免疫治療研究的快速進展

市場概況
預測期	2024-2028
2022 年市場規模	324.9億美元
2028 年市場規模	524.4億美元
2023-2028 年CAGR	8.49%
成長最快的細分市場	亞太地區
最大的市場	北美洲

免疫治療研究的快速進展將推動全球檢查點抑制劑難治性癌症市場的成長。隨著創新療法的出現，解決檢查點抑制劑難治性癌症帶來的挑戰，預計市場需求將激增。免疫療法能夠利用人體的免疫系統來對抗癌症，是研究的焦點，為治療抗藥性病例提供了新的途徑。這些突破為醫療保健提供者和利害關係人注入了信心，為市場擴張創造了有利的環境。隨著臨床試驗的持續進行和治療方案的不斷發展，市場正在見證檢查點抑制劑難治性癌症治療的革命性轉變。改善患者治療效果和提高存活率的承諾正在推動製藥和生物技術領域的投資和合作。隨著監管批准和商業化策略與研究里程碑一致，全球檢查點抑制劑難治性癌症市場將經歷大幅成長。利害關係人應該對自己進行策略定位，以利用這些進步，並認知到在這個動態和不斷變化的環境中實現醫學突破和獲利商業機會的潛力。

市場規模及預測
- 按價值
市佔率及預測
- 按類型（PD-1 抑制劑、PD-L1 抑制劑、其他）
- 按應用（肺癌、膀胱癌、黑色素瘤、何杰金氏淋巴瘤等）
- 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
- 按公司分類 (2022)
市場地圖
- 按類型
- 按應用
- 按地區

第 6 章：北美檢查點抑制劑難治性癌症市場展望

市場規模及預測
- 按價值
市佔率及預測
- 按類型（PD-1 抑制劑、PD-L1 抑制劑、其他）
- 按應用（肺癌、膀胱癌、黑色素瘤、何杰金氏淋巴瘤等）
- 按國家/地區
北美：國家分析
- 美國
- 加拿大
- 墨西哥

第 7 章：歐洲檢查點抑制劑難治性癌症市場展望

市場規模及預測
- 按價值
市佔率及預測
- 按類型（PD-1 抑制劑、PD-L1 抑制劑、其他）
- 按應用（肺癌、膀胱癌、黑色素瘤、何杰金氏淋巴瘤等）
- 按國家/地區
歐洲：國家分析
- 法國
- 德國
- 英國
- 義大利
- 西班牙

第 8 章：亞太檢查點抑制劑難治性癌症市場展望

市場規模及預測
- 按價值
市佔率及預測
- 按類型（PD-1 抑制劑、PD-L1 抑制劑、其他）
- 按應用（肺癌、膀胱癌、黑色素瘤、何杰金氏淋巴瘤等）
- 按國家/地區
亞太地區：國家分析
- 中國
- 印度
- 日本
- 韓國
- 澳洲

第 9 章：南美洲檢查點抑制劑難治性癌症市場展望

市場規模及預測
- 按價值
市佔率及預測
- 按類型（PD-1 抑制劑、PD-L1 抑制劑、其他）
- 按應用（肺癌、膀胱癌、黑色素瘤、何杰金氏淋巴瘤等）
- 按國家/地區
南美洲：國家分析
- 巴西
- 阿根廷
- 哥倫比亞

第 10 章：中東和非洲檢查點抑制劑難治性癌症市場展望

市場規模及預測
- 按價值
市佔率及預測
- 按類型（PD-1 抑制劑、PD-L1 抑制劑、其他）
- 按應用（肺癌、膀胱癌、黑色素瘤、何杰金氏淋巴瘤等）
- 按國家/地區
MEA：國家分析
- 南非檢查點抑制劑難治性癌症
- 沙烏地阿拉伯檢查點抑制劑難治性癌症
- 阿拉伯聯合大公國檢查點抑制劑難治性癌症

第 11 章：市場動態

促進要素
挑戰

第 12 章：市場趨勢與發展

近期發展
併購
產品發布

第 13 章：全球檢查點抑制劑難治性癌症市場：SWOT 分析

第 14 章：波特的五力分析

產業競爭
新進入者的潛力
供應商的力量
客戶的力量
替代產品的威脅

第15章：競爭格局

百時美施貴寶公司。
- Business Overview
- Product Offerings
- Recent Developments
- Financials (As Reported)
- Key Personnel
- SWOT Analysis
阿斯特捷利康公司
默克公司
F.霍夫曼-拉羅氏有限公司
再生元製藥公司
輝瑞公司
楊森全球服務有限公司
4SC公司
米拉蒂治療公司
亞盛醫藥。

第 16 章：策略建議

簡介目錄

Product Code: 20171

Global Checkpoint Inhibitor Refractory Cancer Market has valued at USD 32.49 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 8.49% through 2028. Checkpoint inhibitors are a type of immunotherapy that works by blocking certain proteins in cancer cells, allowing the immune system to recognize and attack cancer more effectively. Cancer is a major cause of morbidity and mortality worldwide. As the global population ages, the incidence of cancer is expected to increase, creating a growing demand for cancer treatments including checkpoint inhibitor refractory cancer market. According to the World Health Organization, Cancer is one of the leading causes of death worldwide, killing nearly 10 million people in 2020, or nearly one in six. For instance, The Chinese People's Liberation Army General Hospital is conducting a phase I trial of GSL synthetase inhibitors alone or in combination with immune checkpoint inhibitors in the treatment of patients with advanced relapsed or refractory hematologic malignancies and previously treated solid tumors.

Key Market Drivers

Rapid Advances in Immunotherapy Research

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 32.49 Billion
Market Size 2028	USD 52.44 Billion
CAGR 2023-2028	8.49%
Fastest Growing Segment	Asia Pacific
Largest Market	North America

Rapid advances in immunotherapy research are poised to propel the growth of the Global Checkpoint Inhibitor Refractory Cancer Market. As innovative therapies emerge, addressing the challenges posed by checkpoint inhibitor refractory cancers, a surge in market demand is anticipated. Immunotherapy, with its ability to harness the body's immune system to combat cancer, is a focal point of research, offering new avenues for treatment-resistant cases. These breakthroughs instill confidence among healthcare providers and stakeholders, creating a conducive environment for market expansion. With ongoing clinical trials and evolving treatment protocols, the market is witnessing a transformative shift in the management of checkpoint inhibitor refractory cancers. The promise of enhanced patient outcomes and improved survival rates is driving investments and collaborations within the pharmaceutical and biotechnology sectors. As regulatory approvals and commercialization strategies align with research milestones, the Global Checkpoint Inhibitor Refractory Cancer Market is set to experience substantial growth. Stakeholders should strategically position themselves to capitalize on these advancements, recognizing the potential for both medical breakthroughs and profitable business opportunities in this dynamic and evolving landscape.

Burgeoning Understanding of Tumor Microenvironment

The burgeoning understanding of the tumor microenvironment (TME) is poised to be a catalyst for driving growth in the Global Checkpoint Inhibitor Refractory Cancer Market. As researchers delve deeper into the intricacies of the TME, a nuanced comprehension of the complex interplay between cancer cells and their surrounding environment is emerging. This deeper insight enables the development of targeted therapies that address the unique challenges posed by checkpoint inhibitor refractory cancers within the TME. Innovations stemming from this enhanced understanding are paving the way for novel treatment strategies, offering a more tailored and effective approach to combat resistant cancers. Pharmaceutical companies are increasingly focusing on TME-centric drug development, with a growing pipeline of therapeutics designed to modulate the immune response in the specific context of the tumor's microenvironment. Investors and industry stakeholders are recognizing the pivotal role of TME research in reshaping the landscape of checkpoint inhibitor refractory cancer treatment. Strategic collaborations and investments in technologies that decipher the TME intricacies are becoming key drivers for market growth. This evolving paradigm underscores the imperative for businesses to align their strategies with the expanding knowledge of TME, positioning themselves to capitalize on the opportunities arising in the dynamic Global Checkpoint Inhibitor Refractory Cancer Market.

Government Initiatives and Regulatory Support

Government initiatives and regulatory support are anticipated to be pivotal drivers in propelling the growth of the Global Checkpoint Inhibitor Refractory Cancer Market. Increased recognition of the pressing need for innovative solutions in cancer treatment has prompted governments worldwide to foster an environment conducive to research and development. Robust funding programs and grants are incentivizing pharmaceutical and biotechnology companies to invest in the development of novel therapies targeting checkpoint inhibitor refractory cancers. Furthermore, regulatory bodies are actively streamlining approval processes and providing accelerated pathways for breakthrough treatments, facilitating a more efficient route to market for these specialized drugs. The alignment of regulatory frameworks with the urgency of addressing unmet medical needs in oncology creates a supportive ecosystem for industry players. As governments and regulatory agencies prioritize the advancement of cancer therapeutics, businesses operating in the checkpoint inhibitor refractory cancer space stand to benefit from reduced development timelines and enhanced market access. The collaborative efforts between public institutions and private enterprises foster an environment where innovation flourishes, laying the foundation for sustained growth in the Global Checkpoint Inhibitor Refractory Cancer Market. Companies should strategically position themselves to leverage these supportive measures and contribute to the evolving landscape of cancer care.

Key Market Challenges

Intrinsic Tumor Heterogeneity

Intrinsic tumor heterogeneity presents a formidable obstacle that can impede the growth of the Global Checkpoint Inhibitor Refractory Cancer Market. The inherent diversity in genetic and molecular profiles within tumors of individual patients poses challenges in developing universally effective therapies. This complexity complicates the identification of specific targets for checkpoint inhibitors, hindering the creation of treatments that can comprehensively address the varied facets of tumor heterogeneity. The intricate landscape of intrinsic tumor heterogeneity not only extends the timelines and costs associated with drug development but also raises uncertainties regarding treatment outcomes. Tailoring therapies to the unique genetic makeup of each patient becomes a daunting task, demanding sophisticated diagnostic tools and personalized treatment strategies. The market's growth potential is hampered as the demand for precision medicine intensifies. Addressing intrinsic tumor heterogeneity necessitates innovative solutions such as advanced genomic profiling and artificial intelligence-driven analytics to unravel the complexities of individual tumors. Industry players must navigate these challenges strategically, investing in technologies that enable a nuanced understanding of tumor heterogeneity to ensure the development of more targeted and efficacious checkpoint inhibitor refractory cancer treatments.

Limited Biomarker Validation

Limited biomarker validation stands as a formidable hindrance to the growth of the Global Checkpoint Inhibitor Refractory Cancer Market. Biomarkers are pivotal in identifying patients who would benefit most from checkpoint inhibitor therapies, aiding in treatment selection and predicting responses. However, the insufficient validation of these biomarkers introduces uncertainties, impacting the reliability and effectiveness of treatment strategies. The absence of widely validated biomarkers impedes the development of targeted therapies and complicates the regulatory approval process. Healthcare providers face challenges in accurately identifying eligible patients, potentially leading to suboptimal treatment outcomes and increased healthcare costs. The industry's ability to deliver personalized and precision medicine is stymied, as the lack of validated biomarkers undermines the confidence of clinicians and investors alike. Addressing this bottleneck requires substantial investment in rigorous clinical validation studies and collaborative efforts between pharmaceutical companies, research institutions, and regulatory bodies. Successful biomarker validation not only enhances treatment efficacy but also fosters greater confidence in the market, ultimately driving widespread adoption of checkpoint inhibitor refractory cancer therapies and fueling the market's sustained growth.

Key Market Trends

Combination Therapies and Synergistic Approaches

The growth of the Global Checkpoint Inhibitor Refractory Cancer Market is poised to be significantly propelled by the adoption of combination therapies and synergistic approaches. Recognizing the complex nature of cancer, pharmaceutical companies are increasingly exploring the synergies between checkpoint inhibitors and complementary treatments, such as targeted therapies, immunomodulators, or traditional chemotherapy. Combination therapies offer a multi-faceted approach, addressing diverse mechanisms involved in tumor resistance and enhancing overall treatment effectiveness. Synergistic combinations not only improve response rates but also have the potential to overcome intrinsic and acquired resistance to checkpoint inhibitors. This strategic approach is reshaping the treatment landscape, providing more comprehensive solutions for patients with refractory cancers. The market's growth is driven by the accelerated development and clinical validation of these combination therapies, supported by collaborative efforts among industry stakeholders, research institutions, and regulatory bodies. Investors are increasingly attracted to the potential of these innovative treatment approaches, fostering a dynamic ecosystem that encourages further advancements. As combination therapies demonstrate improved clinical outcomes and gain regulatory approvals, they are expected to become a cornerstone in the management of checkpoint inhibitor refractory cancers, driving sustained market growth and offering new avenues for therapeutic innovation. Industry players should position themselves strategically to capitalize on these emerging opportunities in the evolving landscape of cancer treatment.

Focus on Tumor Microenvironment Modulation

The growth trajectory of the Global Checkpoint Inhibitor Refractory Cancer Market is being markedly influenced by a strategic focus on tumor microenvironment (TME) modulation. Recognizing the pivotal role of TME in influencing treatment responses, pharmaceutical and biotech companies are intensifying efforts to develop therapies that specifically target and modulate the microenvironment surrounding cancer cells. Innovations in TME modulation involve tailoring treatments to disrupt the immunosuppressive elements within the tumor, making it more susceptible to checkpoint inhibitor therapies. This approach not only enhances the efficacy of checkpoint inhibitors but also addresses the challenges posed by tumor heterogeneity and resistance. This strategic emphasis on TME modulation is attracting significant investments and fostering collaborations across the industry. As promising preclinical and clinical results emerge, regulatory bodies are increasingly recognizing the importance of these advancements, expediting the development and approval processes. The evolving landscape, driven by a keen focus on TME, is reshaping the market dynamics, offering a paradigm shift in the treatment of checkpoint inhibitor refractory cancers. Companies that position themselves at the forefront of TME modulation research are likely to drive the market's growth, providing innovative solutions that meet the urgent medical needs in this specialized therapeutic domain.

Segmental Insights

Type Insights

Based on the Type, the PD-1 Inhibitor segment is anticipated to witness substantial market growth throughout the forecast period. The growth of the Global Checkpoint Inhibitor Refractory Cancer Market is strongly influenced by the prominence of PD-1 inhibitors. PD-1 inhibitors, a class of immunotherapies, play a pivotal role in unleashing the body's immune response against cancer cells by blocking the programmed cell death protein 1 pathway. As a cornerstone of checkpoint inhibitor therapy, PD-1 inhibitors have demonstrated significant efficacy in various cancers. Their widespread adoption stems from their ability to overcome resistance mechanisms and address checkpoint inhibitor refractory cases. PD-1 inhibitors exhibit versatility, showing promise across diverse tumor types, thereby expanding their market applicability. As a result, pharmaceutical companies are investing heavily in the development and clinical validation of PD-1 inhibitors, both as monotherapies and in combination with other agents. The market's growth is driven by the expanding repertoire of PD-1 inhibitors, supported by robust clinical evidence and regulatory approvals. As the demand for effective checkpoint inhibitor refractory cancer treatments intensifies, PD-1 inhibitors are positioned to be key revenue generators, shaping the market landscape and driving innovation in immunotherapeutic approaches. Industry stakeholders should strategically position themselves to capitalize on the immense potential of PD-1 inhibitors in meeting the evolving needs of cancer patients globally.

Application Insights

Based on the Application segment, the Hodgkin Lymphoma segment has been the dominant force in the market. The growth of the Global Checkpoint Inhibitor Refractory Cancer Market is set to be significantly driven by the unique position of Hodgkin Lymphoma (HL) within this therapeutic landscape. Hodgkin Lymphoma, characterized by the presence of Reed-Sternberg cells, has demonstrated a notable responsiveness to checkpoint inhibitors, particularly PD-1 inhibitors like pembrolizumab and nivolumab. As a flagship indication for checkpoint inhibitor success, the positive clinical outcomes in refractory or relapsed Hodgkin Lymphoma cases have underscored the potential of these immunotherapies. The remarkable efficacy in HL has led to expanded regulatory approvals and an increasing acceptance of checkpoint inhibitors as a standard treatment option. The success in HL not only establishes checkpoint inhibitors as a viable therapeutic approach but also serves as a catalyst for broader applications across various cancers. This has attracted substantial investments from pharmaceutical companies and heightened interest from clinicians, driving research and development efforts. The unique dynamics of Hodgkin Lymphoma, acting as a trailblazer in checkpoint inhibitor refractory cancers, positions it as a key driver for the overall market growth. Industry players should leverage these insights, focusing on advancements in checkpoint inhibitors for HL, to capitalize on the expanding opportunities within the evolving landscape of cancer therapeutics.

Regional Insights

North America, specifically the Checkpoint Inhibitor Refractory Cancer Market, dominated the market in 2022, primarily due to The North America region is poised to be a major driver in propelling the growth of the Global Checkpoint Inhibitor Refractory Cancer Market. With its robust healthcare infrastructure, strong research and development capabilities, and a substantial market demand for advanced cancer therapies, North America stands as a primary hub for the development and commercialization of checkpoint inhibitors. The region benefits from a progressive regulatory environment that expedites the approval process for novel cancer treatments, providing a conducive landscape for pharmaceutical and biotech companies. Moreover, the presence of key industry players, cutting-edge research institutions, and a high level of healthcare expenditure contribute to the region's leadership in advancing checkpoint inhibitor research. Additionally, a well-established network of oncology clinics and a patient population actively seeking innovative cancer treatments further drive the market's growth. As North America continues to witness collaborations between industry and academia, coupled with strategic investments in immunotherapeutic advancements, it solidifies its position as a frontrunner in steering the expansion of the Global Checkpoint Inhibitor Refractory Cancer Market. Companies aiming to capitalize on this growth trajectory should strategically position themselves within this dynamic and influential market.

Key Market Players

Bristol-Myers Squibb Company.

AstraZeneca plc.

Merck KGaA

F. Hoffmann-La Roche Ltd

Regeneron Pharmaceuticals Inc

Pfizer Inc

Janssen Global Services, LLC

4SC AG

Mirati Therapeutics, Inc.

Ascentage Pharma.

Report Scope:

In this report, the Global Checkpoint Inhibitor Refractory Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Checkpoint Inhibitor Refractory Cancer Market, By Type:

PD-1 Inhibitor
PD-L1 Inhibitor
Others

Checkpoint Inhibitor Refractory Cancer Market, By Application:

Lung Cancer
Bladder Cancer
Melanoma
Hodgkin Lymphoma
Others

Checkpoint Inhibitor Refractory Cancer Market, By Region:

North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Turkey
Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Checkpoint Inhibitor Refractory Cancer Market.

Available Customizations:

Global Checkpoint Inhibitor Refractory Cancer market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Checkpoint Inhibitor Refractory Cancer Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (PD-1 Inhibitor, PD-L1 Inhibitor, Others)
- 5.2.2. By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Others)
- 5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
- 5.2.4. By Company (2022)
5.3. Market Map
- 5.3.1 By Type
- 5.3.2 By Application
- 5.3.3 By Region

6. North America Checkpoint Inhibitor Refractory Cancer Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type (PD-1 Inhibitor, PD-L1 Inhibitor, Others)
- 6.2.2. By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Others)
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Application
- 6.3.2. Canada Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Application
- 6.3.3. Mexico Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Application

7. Europe Checkpoint Inhibitor Refractory Cancer Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type (PD-1 Inhibitor, PD-L1 Inhibitor, Others)
- 7.2.2. By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Others)
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Application
- 7.3.2. Germany Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Application
- 7.3.3. United Kingdom Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Application

8. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type (PD-1 Inhibitor, PD-L1 Inhibitor, Others)
- 8.2.2. By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Others)
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Application
- 8.3.2. India Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Application
- 8.3.3. Japan Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Application
- 8.3.4. South Korea Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Application
- 8.3.5. Australia Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Application

9. South America Checkpoint Inhibitor Refractory Cancer Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type (PD-1 Inhibitor, PD-L1 Inhibitor, Others)
- 9.2.2. By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Others)
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Application
- 9.3.2. Argentina Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Application
- 9.3.3. Colombia Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Application

10. Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type (PD-1 Inhibitor, PD-L1 Inhibitor, Others)
- 10.2.2. By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Others)
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Application
- 10.3.2. Saudi Arabia Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Application
- 10.3.3. UAE Checkpoint Inhibitor Refractory Cancer Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Global Checkpoint Inhibitor Refractory Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Bristol-Myers Squibb Company.
- 15.1.1. Business Overview
- 15.1.2. Product Offerings
- 15.1.3. Recent Developments
- 15.1.4. Financials (As Reported)
- 15.1.5. Key Personnel
- 15.1.6. SWOT Analysis
15.2. AstraZeneca plc.
15.3. Merck KGaA
15.4. F. Hoffmann-La Roche Ltd
15.5. Regeneron Pharmaceuticals Inc
15.6. Pfizer Inc
15.7. Janssen Global Services, LLC
15.8. 4SC AG
15.9. Mirati Therapeutics, Inc.
15.10. Ascentage Pharma.